Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress

Impact · against what's priced in

ACRV provides a concrete catalyst for the stock with the announcement of a late-breaking oral presentation of Phase 2b interim data for ACR-368. The visibility of this data release in February creates a near-term volatility window for a registrational-intent trial.

ACRV+0.60

No priced-in read yet